Citations

Clear

219 citation(s) found for "Do, Ron".

CNS manifestations in acute and chronic graft-versus-host disease
Lambert, Nicolas , Forte, Florence, Monseur, Justine, Raus, Nicole, Shultz, Carl , Balaguer‐Roselló, Aitana , Gil‐Perotín, Sara , Brijs, Jan , Chauvet, Paul , Carré, Martin , Dulămea, Adriana Octaviana , Salmenniemi, Urpu , Nguyen, Stéphanie , Smallbone, Portia , González‐Vicent, Marta , Willems, Évelyne, Baron, Frédéric , Servais, Sophie , Béguin, Yves , Maquet, Pierre , Group, the CNS-GvHD Study, Lambert, Nicolas, Monseur, Justine, Raus, Nicole, Shultz, Carl, Brijs, Jan, Gavriilaki, Maria, Dulamea, Adriana Octaviana, Tănase, Alina , Salmenniemi, Urpu, Butera, Sara , Piekarska, Agnieszka , Davies, J. M., Labussière-Wallet, Hélène, D’Aveni, Maud , Willems, Evelyne, Gil-Perotín, Sara , Chalandon, Yves , Santoro, Jonathan D , Servais, Sophie , Lambert, Nicolas , Moussaoui, Majdouline El , Raus, Nicole, Polushin, Alexey Yu. , Michonneau, David , Hogan, William J. , Gavriilaki, Maria , Chalandon, Yves , Duminuco, Andrea , Ram, Ron , García‐Cadenas, Irene , Porto, Gaetana , Santoro, Jonathan D. , Group, the CNS-GvHD Study, Lambert, Nicolas, Monseur, Justine, Raus, Nicole, Skiba, Iaroslav B. , Shultz, Carl, Brijs, Jan, Gavriilaki, Maria, Sakellari, Ioanna , Dulamea, Adriana Octaviana, Chantepie, Sylvain , Salmenniemi, Urpu, Loschi, Michael L. , Martino, Massimo , Mensah‐Glanowska, Patrycja , Labussière-Wallet, Hélène, Hamadani, Mehdi , Willems, Evelyne

Mayo Clinic

Brain | October 23, 2024 | Volume: 148 | Issue: 4 | Pages: 1122-1133

10.1093/brain/awae340 | PMID 39442000 Get It

Abstract Despite the growing evidence supporting the existence of CNS involvement in acute and chronic graft-versus-host disease (CNS-GvHD), the characteristics and course of the disease are still largely unknown. In this multicentre retrospective study, we analysed the clinical, biological, radiological and histopathological characteristics, as well as the clinical course of 66 patients diagnosed with possible CNS-GvHD (pCNS-GvHD), selected by predetermined diagnostic criteria. Results were then contrasted depending on whether pCNS-GvHD onset occurred before or after Day 100 following allogeneic haematopoietic stem cell transplantation (allo-HSCT). The median time between allo-HSCT and pCNS-GvHD onset was 149 days (interquartile range25–75 48–321), and pCNS-GvHD onset occurred before Day 100 following transplantation in 44% of patients. The most frequent findings at presentation were cognitive impairment (41%), paresis (21%), altered consciousness (20%), sensory impairment (18%) and headache (15%). Clinical presentation did not significantly differ between patients with pCNS-GvHD occurring before or after Day 100 following transplantation. Brain MRI found abnormalities compatible with the clinical picture in 57% of patients, while CT detected abnormalities in only 7%. Seven patients had documented spinal cord MRI abnormalities, all of them with pCNS-GvHD occurring after Day 100 following transplantation. In the CSF, the white blood cell count was increased in 56% of the population (median 18 cells/μl). Histopathological analyses were performed on 12 specimens and were suggestive of pCNS-GvHD in 10. All compatible specimens showed parenchymal and perivascular infiltration by CD3+ and CD163+ cells. Immunosuppressive therapy was prescribed in 97% of patients, achieving complete clinical response in 27%, partial improvement in 47% and stable disease in 6%. Response to immunosuppressive therapy did not differ significantly between patients with pCNS-GvHD occurring before or after Day 100 following transplantation. Clinical relapse was observed in 31% of patients who initially responded to treatment. One-year overall survival following pCNS-GvHD onset was 41%. Onset before Day 100 following haematopoietic stem cell transplantation [hazard ratio with 95% confidence interval: 2.1 (1.0–4.5); P = 0.041] and altered consciousness at initial presentation [3.0 (1.3–6.7); P = 0.0077] were associated with a reduced 1-year overall survival probability. Among surviving patients, 61% had neurological sequelae. This study supports that immune-mediated CNS manifestations may occur following allo-HSCT. These can be associated with both acute and chronic GvHD and carry a grim prognosis. The clinical presentation as well as the radiological and biological findings appear variable.
Longitudinal graphics of physical function and other patient-reported outcomes in patients treated for hematologic malignancies 
Thanarajasingam, Gita , Chen, Tingyu , Hoffman, Ron, Mascarenhas, John , Murugappan, Meena N. , Ross, Joseph F., Warsame, Rahma , Dueck, Amylou C. , Dueck, A. C. , Bhatnagar, Vishal , Noble, Brie N. , Fiero, Mallorie H. , Jeffery, Molly Moore , Mazza, Gina L , Mascarenhas, John , Mesa, Ruben A. , Ross, Joseph, Sidana, Surbhi , Kluetz, Paul Gustav

Mayo Clinic

No container title available | October 11, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4888383/v1 Get It

Abstract Background The US Food and Drug Administration (FDA) released a draft guidance document detailing core patient-reported outcomes in cancer clinical trials, including physical function (PF). This study aimed to develop analytic methods and visualizations of patient-reported PF in patients with cancer. Methods We applied an estimand framework to a patient-reported tolerability endpoint to develop data summaries cross-sectionally and over time, along with visualizations. We accomplished this through iterative feedback with clinicians, statisticians, and FDA stakeholders using three clinical trial datasets in hematologic malignancies. Graphical approaches were applied to three datasets in hematologic malignancies: (1) patients with myeloproliferative neoplasms enrolled in MPN-RC 111/112 trials completed EORTC QLQ-C30 over 12 months; (2) patients with hematologic malignancies undergoing CAR-T cell therapy or autologous transplant who completed FACT questionnaires over 6 months; and (3) patients with multiple myeloma or amyloidosis who completed the PROMIS-29 questionnaire over 6 months. Zoom polls were administered to two stakeholder groups (clinicians/clinical investigators and patient advocates) to elicit feedback. Results Visualizations included stacked bar charts, line plots of arithmetic mean changes from baseline, pie charts, waffle plots, and waterfall plots of PF data. Graphics considered scaled scores and individual items and included delineation of PRO completion rate at each time point. Confidence intervals and reference lines were included as applicable, and colorblind accessible colors were implemented to ensure inclusivity of all visualizations. Data summaries over time reporting “worst” change were difficult to interpret. In terms of stakeholders’ preference, patients preferred stacked bar charts while clinicians equally favored stacked bar charts and line plots; both patients and clinicians preferred waterfall plots to pie charts. Patient feedback highlighted the need for various graphics to convey group level trends and granular individual-patient level information. Conclusion Patient-reported PF informs the evaluation of treatment tolerability in cancer trials. Data summaries and visualizations of physical function developed through an iterative process were reviewed favorably by patients, clinicians and FDA stakeholders in this study. Future work to systematically assess accuracy of interpretation of the various analytic and visualization methods is a necessary next step across clinical, regulatory, payer and patient stakeholders. Trial registration NCT01259817, NCT01259856
Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Lemaı̂tre, F. , Barten, Markus J. , Bergan, Stein , Shipkova, Maria , Vinks, Sander, Wieland, Eberhard , Bornemann-Kolatzki, Kirsten , Brunet, Mercè , Winter, Brenda C. M. de , Ito, Taihei, Johnson‐Davis, Kamisha L. , Kunicki, Paweł K. , Lawson, Roland , Lloberas, Núria , Marquet, Pierre , Millán, Olga , Mizuno, Tomoyuki , Noceti, Ofelia , Oellerich, Michael , Pattanaik, Smita , Seger, Christoph , Schaik, Ron HN van , Venkataramanan, Raman , Walson, Phil, Woillard, Jean‐Baptiste , Langman, Loralie J., Masuda, Satohiro , Lemaitre, Florian, Gelder, Teun van , Vinks, Sander, Dieterlen, Maja‐Theresa , Elens, Laure , Moes, Dirk Jan A. R. , Pawiński, Tomasz , Walson, Philip D.

Mayo Clinic

Therapeutic Drug Monitoring | September 27, 2024 | Volume: 47 | Issue: 1 | Pages: 4-31

10.1097/ftd.0000000000001250 | PMID 39331837 Get It

Abstract: The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of EVR that have retained their relevance, readers can refer to the 2016 document. This edition includes new evidence from the literature, focusing on the topics updated during the last 7 years, including indirect pharmacological effects of EVR on the mammalian target of rapamycin complex 2 with the major mechanism of direct inhibition of the mammalian target of rapamycin complex 1. In addition, various concepts and technical options to monitor EVR concentrations, improve analytical performance, and increase the number of options available for immunochemical analytical methods have been included. Only limited new pharmacogenetic information regarding EVR has emerged; however, pharmacometrics and model-informed precision dosing have been constructed using physiological parameters as covariates, including pharmacogenetic information. In clinical settings, EVR is combined with a decreased dose of calcineurin inhibitors, such as tacrolimus and cyclosporine, instead of mycophenolic acid. The literature and recommendations for specific organ transplantations, such as that of the kidneys, liver, heart, and lungs, as well as for oncology and pediatrics have been updated. EVR TDM for pancreatic and islet transplantation has been added to this edition. The pharmacodynamic monitoring of EVR in organ transplantation has also been updated. These updates and additions, along with the previous version of this consensus document, will be helpful to clinicians and researchers treating patients receiving EVR.
Iltamiocel Autologous Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Double‐Blind, Randomized, Stratified, Placebo‐Controlled Trial
Kaufman, Melissa R. , Goldman, Howard B. , Chermansky, Christopher , Dmochowski, Roger R. , Peters, Kenneth M. , Quiroz, Lieschen H. , Bennett, Jason , Thomas, Sherry , Marguet, Charles G., Benson, Kevin , Wolter, Christopher , Katz, Daniel , Tarnay, Christopher M. , Antosh, Danielle D. , Heit, Michael , Rehme, Christian, Karram, Mickey M., Canestrari, Emanuele , Jankowski, Ron J. , Chermansky, Christopher J , Dmochowski, Roger , Lee, Una J , Wolter, Christopher E, Canestrari, Emanuele , Jankowski, Ron J , Chancellor, Michael B , KENNELLY, MICHAEL J. , Sokol, Eric R. , Katz, Daniel M., Snyder, Scott

Mayo Clinic

Neurourology and Urodynamics | September 16, 2024 | Volume: 43 | Issue: 8 | Pages: 2290-2299

10.1002/nau.25588 | PMID 39282854 Get It

ABSTRACTAimsThis study aimed to determine the efficacy and safety of iltamiocel investigational autologous muscle cell therapy in females with stress urinary incontinence (SUI).MethodsAdult females were randomized 2:1 to iltamiocel (150 × 106 cells) or placebo and stratified by severity and prior SUI surgery. The primary objective was efficacy based on the frequency of stress incontinence episodes (SIE) recorded in a 3‐day diary at 12 months posttreatment. After 12 months, placebo participants could elect to receive open‐label iltamiocel. Efficacy and safety analyses were performed using all patients as treated populations.ResultsThe study enrolled 311 patients, 297 were randomized to either iltamiocel (n = 199) or placebo (n = 98). Of the 295 participants that completed 12 months blinded follow‐up, the proportion achieving the primary endpoint of ≥ 50% SIE reduction was not statistically different between treatment groups (52% vs. 53.6%; p = 0.798). A significantly greater proportion of iltamiocel participants in the prior SUI surgery stratum group achieved ≥ 75% SIE reduction compared with placebo, (40% vs. 16%; p = 0.037). Treatment response was maintained at 24 months in 78.4% and 64.9% of iltamiocel participants who achieved ≥ 50% and ≥ 75% SIE reduction, respectively, at Month 12. Adverse events related to the treatment were reported in 19 (9.5%) iltamiocel participants and 6 (6.1%) placebo participants.ConclusionThe study did not meet its primary endpoint however, iltamiocel cell therapy is safe and may be ideally suited to female patients who have undergone prior surgery for SUI. Additional study in this group of patients with high unmet medical needs is warranted.Trial RegistrationClinicalTrials.gov identifier: NCT01893138; EudraCT number: 2014‐002919‐41.
Associations Between Running Mechanics, Functional Lower Extremity Strength, and Stress Urinary Incontinence in Parous Female Runners
Ron, Nicole J., Dolbinski, Sarah C., Hodonicky, Elizabeth G., Middlebrook, Darby O., Olmstead, Sally R., Olsen, Sandra L., Ron, Eyal D. , Middlebrook, Darby O., Olsen, Sandra L., Hollman, John H.

Mayo Clinic

Journal of Women's & Pelvic Health Physical Therapy | July 17, 2024 | Volume: 48 | Issue: 3 | Pages: 147-153

10.1097/jwh.0000000000000302 | PMID 39148952 Get It

Background: Women with stress urinary incontinence (SUI) may have altered running mechanics and reduced hip muscle strength compared with women without SUI. Little research has examined running metrics and functional lower extremity strength of parous runners. Objective: To determine whether SUI severity correlates with running metrics and lower extremity muscle strength among parous women. Study Design: This was a cross-sectional observational study of 22 parous participants (mean age 39.8 years, with a mean of 3.4 pregnancies and 8.1-year interval since last delivery). Methods: Participants completed the International Consultation on Incontinence Questionnaire–Urinary Incontinence Short Form (ICIQ-UI), Urinary Distress Inventory-6 (UDI-6), Colorectal-Anal Distress (CRAD) Inventory-8, and Pelvic Organ Prolapse Distress Inventory-6 (POPDI-6), and Questionnaire for Urinary Incontinence Diagnosis (QUID) and provided demographic, relevant running, and obstetric/gynecologic history information. After a brief warm-up, participants completed 30-second single-leg sit-to-stand tests bilaterally and a standardized 10-minute treadmill run with pod cadence assessment. Pearson-product moment correlation coefficients were calculated (α = .05). Results: Prolonged ground contact times were associated with higher ICIQ-UI SF (r= 0.523, P= .015), POPDI-6 (r= 0.694, P< .001), and UDI-6 scores (r= 0.577, P= .006), while lower cadences were associated with higher POPDI-6 (r=−0.550, P= .010) and UDI-6 scores (r=−0.444, P= .044). Conclusions: Parous female runners with more severe SUI and prolapse symptoms demonstrate altered running mechanics characterized by prolonged ground contact times and slower cadences.
Preliminary Study of Motion Preservation Following Posterior Dynamic Distraction Device in Adolescent Idiopathic Scoliosis Patients
Todderud, Julia E , Milbrandt, Todd A. , Floyd, Edward R. , Haft, Geoffrey F. , Albert, Michael , Larson, A. Noelle , Larson, A Noelle , Floyd, Edward, El‐Hawary, Ron

Mayo Clinic

Journal of Pediatric Orthopaedics | July 1, 2024 | Volume: 44 | Issue: 9 | Pages: 524-529

10.1097/bpo.0000000000002739 | PMID 38946041 Get It

Background: Motion-sparing scoliosis surgeries such as the posterior dynamic distraction device (PDDD) are slowly increasing in use. However, there is limited clinical data documenting postoperative motion across the PDDD construct. With this cohort study, we aim to measure sagittal and coronal motion following PDDD. We hypothesize coronal and sagittal spinal motion will be partially preserved across the construct. Methods: Retrospective review of prospectively collected data. Preoperative and minimum 1-year postoperative coronal range of motion across the instrumented levels was compared. Available flexion/extension radiographs were evaluated postoperatively to assess sagittal arc of motion. Radiographs from latest follow-up were used. Results: At a mean of 1.9 years (1 to 5 y), flexibility radiographs were available on 29 patients treated with PDDD (17 thoracic, 12 lumbar). Mean age at surgery was 16 years (12 to 25). Postoperative coronal arc of motion in PDDD patients was 11 degrees (3 to 19 degrees) in the thoracic spine and 10 degrees (0 to 28 degrees) in the lumbar spine. Compared with preoperative motion, the thoracic arc of motion was maintained by 33% (35 to 11 degrees) and lumbar motion was maintained by 30% (34 to 10 degrees). Flexion-extension radiographs were available on 7 patients. Sagittal arc for the upper instrumented vertebral end plate to the lower instrumented vertebral endplate of the cohort was 10 degrees in the thoracic spine (6 to 18) and 14 degrees in the lumbar spine (5 to 21). Sagittal measurements for the changes in the arc of the upper and lower screws on the construct were 4 degrees in the thoracic group (2 to 8) and 9 degrees in the lumbar group (2 to 17). By latest follow-up 11 patients (38%) underwent reoperation, with most cases due to implant breakage (N=4, 14%), extender misalignment (N=2, 7%), and screw misplacement (N=2, 7%). Conclusion: At mean 1.9 years postoperatively, PDDD preserves measurable spinal motion over the construct both in the coronal and the sagittal plane without evidence for autofusion. Coronal arc of motion averages 10 to 12 degrees and sagittal arc of motion ranged from 4 to 14 degrees, although this varies by patient. This study confirms that PDDD for pediatric scoliosis preserves a measurable degree of postoperative flexibility both in the sagittal and coronal planes. Level of Evidence: Level II—therapeutic study.
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Tarantino, Paolo , Tayob, Nabihah , Villacampa, Guillermo , Dang, Chau T. , Isakoff, Steven J. , Valero, Vicente , Faggen, Meredith, Mulvey, Therese M. , Bose, Ron , Weckstein, Douglas, Reeder‐Hayes, Katherine E. , Ramaswamy, Bhuvaneswari , Zuckerman, Dan Sayam , Hart, Lowell L., Gadi, Vijayakrishna K. , Constantine, Michael, Cheng, Kit , Garrett, Audrey Merrill, Albain, Kathy S. , DeFusco, Patricia, Ardman, Blair, Nanda, Rita , Jankowitz, Rachel C. , Rimawi, Mothaffar F. , Pohlmann, Paula R. , Poznak, Catherine Van , Forero‐Torres, Andres , Liu, Minetta C. , Ruddy, Kathryn J. , Waks, Adrienne G., DeMeo, Michelle K. , Burstein, Harold J. , Dell’Orto, Patrizia , Russo, Leila, Krause, Emma , Newhouse, Daniel , Schneider, Bryan P. , Krop, Ian E. , Tolaney, Sara M. , Curigliano, Giuseppe , Hui, Winnie W. , Kirkup, Christian , Viale, Giuseppe , Prat, Aleix , Isakoff, Steven J , Mulvey, Therese Marie , Bose, Ron , Wolff, Antonio C , Reeder-Hayes, Katherine , Rugo, Hope S , Zuckerman, Dan , Gadi, Vijayakrishna K , Cheng, Kit , Marcom, Paul Kelly , Albain, Kathy , Tung, Nadine , Nanda, Rita , Jankowitz, Rachel C , Rimawi, Mothaffar , Abramson, Vandana G , Van Poznak, Catherine , Forero-Torres, Andres , Liu, Minetta , Ruddy, Kathryn J , Burstein, Harold J , Partridge, Ann H , Krause, Emma , Kurt, Busem Binboğa , Mittendorf, EA , Schneider, Bryan , Prat, Aleix , Winer, Eric , Krop, Ian E , Tolaney, Sara , Prat, Aleix , Curigliano, Giuseppe , Pohlmann, Paula , Yardley, Denise Aysel , Wolff, Antonio C. , Rugo, Hope S. , Tung, Nadine , Abramson, Vandana G. , Waks, Adrienne G. , Partridge, Ann H. , Winer, Eric P. , Barroso‐Sousa, Romualdo , DiLullo, Molly K. , Zheng, Yue

Mayo Clinic

Journal of Clinical Oncology | June 27, 2024 | Volume: 42 | Issue: 31 | Pages: 3652-3665

10.1200/jco.23.02170 | PMID 38935923 Get It

PURPOSE Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)–positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need. METHODS In the ATEMPT phase II trial, patients with stage I centrally confirmed HER2-positive breast cancer were randomly assigned 3:1 to adjuvant T-DM1 for 1 year or paclitaxel plus trastuzumab (TH). Coprimary objectives were to compare the incidence of clinically relevant toxicities between arms and to evaluate invasive disease-free survival (iDFS) with T-DM1. Correlative analyses included the HER2DX genomic tool, multiomic evaluations of HER2 heterogeneity, and predictors of thrombocytopenia. RESULTS After a median follow-up of 5.8 years, 11 iDFS events were observed in the T-DM1 arm, consistent with a 5-year iDFS of 97.0% (95% CI, 95.2 to 98.7). At 5 years, the recurrence-free interval (RFI) was 98.3% (95% CI, 97.0 to 99.7), the overall survival was 97.8% (95% CI, 96.3 to 99.3), and the breast cancer-specific survival was 99.4% (95% CI, 98.6 to 100). Comparable iDFS was observed with T-DM1 irrespective of tumor size, hormone receptor status, centrally determined HER2 immunohistochemical score, and receipt of T-DM1 for more or less than 6 months. Although ATEMPT was not powered for this end point, the 5-year iDFS in the TH arm was 91.1%. Among patients with sufficient tissue for HER2DX testing (n = 187), 5-year outcomes significantly differed according to HER2DX risk score, with better RFI (98.1% v 81.8%, hazard ratio [HR], 0.10, P = .01) and iDFS (96.3% v 81.8%, HR, 0.20, P = .047) among patients with HER2DX low-risk versus high-risk tumors, respectively. CONCLUSION Adjuvant T-DM1 for 1 year leads to outstanding long-term outcomes for patients with stage I HER2-positive breast cancer. A high HER2DX risk score predicted a higher risk of recurrence in ATEMPT.
Associations of mid‐to‐late‐life inflammation with late‐life mobility and the influences of chronic comorbidities, race, and social determinants of health: The Atherosclerosis Risk in Communities Study
Parker, Kirby G., Windham, B. Gwen, Blackshear, Chad , Parker, Sara B., Kucharska‐Newton, Anna , Palta, Priya, Selvin, Elizabeth , Vassilaki, Maria , Mosley, Thomas H., Griswold, Michael , Selvin, Elizabeth , Vassilaki, Maria , Selvin, Elizabeth , Kucharska-Newton, Anna M , Walker, Keenan A. , Hoogeveen, Ron Cornelis , Ballantyne, Christie M. , Mosley, Thomas H.

Mayo Clinic

Journal of the American Geriatrics Society | June 12, 2024 | Volume: 72 | Issue: 8 | Pages: 2434-2445

10.1111/jgs.18978 | PMID 38863338 Get It

Abstract Background Relationships of midlife inflammation with late‐life mobility and influences of chronic health conditions, race, and social determinants of health (SDoH) on these relationships are poorly understood. Methods Among 4758 community‐dwelling participants (41% men, 20% Black), high‐sensitivity C‐reactive protein (hsCRP) was measured over 20+ years: in midlife at study visit 2 (V2: 1990–1992, 47–68 years); at V4 (1996–1998, 53–74 years); and with concurrent late‐life 4‐m gait speed at V5 (2011–2013, 67‐88 years, mean 75 years). SDoH measures included race, the national‐rank area deprivation index, education, and income. We examined associations of late‐life gait speed with midlife hsCRP (V2 continuous and clinically high ≥3 mg/L), with 20‐year hsCRP history from midlife (V2–V5 average continuous hsCRP and clinically high ≥3 mg/L) and with inflammation accumulation (visits and years with high hsCRP). Regression models adjusted for demographic, cardiovascular, and SDoH measures; effect modification by the presence of other common chronic conditions (obesity, diabetes, hypertension) and race were examined, with and without accounting for SDoH. Results High midlife hsCRP was associated with slower late‐life gait speed, even among those without chronic conditions in midlife: −4.6 cm/s (95% CI: −6.4, −2.8). Importantly, sustained high hsCRP was associated with a 20‐year slowing of −10.0 cm/s (−14.9, −5.1) among those who never experienced obesity, diabetes, or hypertension over the 20‐year period. Associations were similar between Black participants, −3.8 cm/s (−6.9, −0.7) and White participants −3.3 (−4.5, −2.2) per interquartile range of midlife hsCRP; effect modifications by chronic conditions and race were unsupported throughout. Results were robust to accounting for SDoH or otherwise; however, worse SDoH was associated with higher inflammation and slower gait speed in both Black and White participants. Conclusions Inflammation in midlife may contribute to clinically meaningful late‐life slowing of gait speed, even among otherwise healthy‐appearing adults and regardless of race and socioeconomic disadvantage. Regular monitoring and interventions for inflammation may be warranted from midlife.
STAGED-PKD: Patient Enrichment and Modeling-Driven Efficient ADPKD Trial Design
Hariri, Ali, Minini, Pascal, Chapman, Arlene B., Horie, Shigeo , Knebelmann, Bertrand , Mrug, Michal , Ong, Albert , Pei, York , Modur, Vijay , Gansevoort, Ron T., Ong, Albert C M , Perrone, Ronald D. , Torres, Vicente E. , Gansevoort, Ronald T.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 502-502

10.1681/asn.20203110s1502b Get It

STAGED-PKD: An Enriched, Seamless, Two-Stage Study for Venglustat Assessment in ADPKD
Hariri, Ali, Minini, Pascal, Chapman, Arlene B., Horie, Shigeo , Knebelmann, Bertrand , Mrug, Michal , Ong, Albert , Pei, York , Modur, Vijay , Gansevoort, Ron T. , Ong, Albert C M , Perrone, Ronald D. , Ahn, Curie , Torres, Vicente E.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 502-502

10.1681/asn.20203110s1502a Get It